Long-Term NSCLC Survivors After Pembrolizumab Show High Survival Rates, Rare Immunotherapy Rechallenge
A nationwide French cohort study reveals that advanced NSCLC patients completing 2 years of pembrolizumab maintain excellent survival outcomes, with most remaining treatment-free and immunotherapy rechallenge being uncommon.